vs

Side-by-side financial comparison of CARTERS INC (CRI) and Organon & Co. (OGN). Click either name above to swap in a different company.

Organon & Co. is the larger business by last-quarter revenue ($1.5B vs $757.8M, roughly 2.0× CARTERS INC). CARTERS INC runs the higher net margin — 1.5% vs -13.6%, a 15.1% gap on every dollar of revenue. On growth, CARTERS INC posted the faster year-over-year revenue change (-0.1% vs -5.3%). Organon & Co. produced more free cash flow last quarter ($96.0M vs $-144.1M).

Carter's, Inc. is a major American designer and marketer of children's apparel. It was founded in 1865 by William Carter.

Organon & Co. is an American pharmaceutical company headquartered in Jersey City, New Jersey. Organon specializes in the following core therapeutic fields: reproductive medicine, contraception, psychiatry, hormone replacement therapy (HRT), and anesthesia. Organon produces all its products outside of the United States but receives a third of its revenue from the United States.

CRI vs OGN — Head-to-Head

Bigger by revenue
OGN
OGN
2.0× larger
OGN
$1.5B
$757.8M
CRI
Growing faster (revenue YoY)
CRI
CRI
+5.3% gap
CRI
-0.1%
-5.3%
OGN
Higher net margin
CRI
CRI
15.1% more per $
CRI
1.5%
-13.6%
OGN
More free cash flow
OGN
OGN
$240.1M more FCF
OGN
$96.0M
$-144.1M
CRI

Income Statement — Q3 FY2026 vs Q4 FY2025

Metric
CRI
CRI
OGN
OGN
Revenue
$757.8M
$1.5B
Net Profit
$11.6M
$-205.0M
Gross Margin
45.1%
49.2%
Operating Margin
3.8%
-9.8%
Net Margin
1.5%
-13.6%
Revenue YoY
-0.1%
-5.3%
Net Profit YoY
-80.1%
-288.1%
EPS (diluted)
$0.32
$-0.78

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CRI
CRI
OGN
OGN
Q4 25
$1.5B
Q3 25
$757.8M
$1.6B
Q2 25
$585.3M
$1.6B
Q1 25
$629.8M
$1.5B
Q4 24
$1.6B
Q3 24
$1.6B
Q2 24
$1.6B
Q1 24
$1.6B
Net Profit
CRI
CRI
OGN
OGN
Q4 25
$-205.0M
Q3 25
$11.6M
$160.0M
Q2 25
$446.0K
$145.0M
Q1 25
$15.5M
$87.0M
Q4 24
$109.0M
Q3 24
$359.0M
Q2 24
$195.0M
Q1 24
$201.0M
Gross Margin
CRI
CRI
OGN
OGN
Q4 25
49.2%
Q3 25
45.1%
53.5%
Q2 25
48.1%
54.8%
Q1 25
46.2%
55.6%
Q4 24
56.3%
Q3 24
58.3%
Q2 24
58.4%
Q1 24
59.0%
Operating Margin
CRI
CRI
OGN
OGN
Q4 25
-9.8%
Q3 25
3.8%
15.2%
Q2 25
0.7%
14.4%
Q1 25
4.1%
6.7%
Q4 24
8.1%
Q3 24
13.1%
Q2 24
14.6%
Q1 24
14.5%
Net Margin
CRI
CRI
OGN
OGN
Q4 25
-13.6%
Q3 25
1.5%
10.0%
Q2 25
0.1%
9.1%
Q1 25
2.5%
5.8%
Q4 24
6.8%
Q3 24
22.7%
Q2 24
12.1%
Q1 24
12.4%
EPS (diluted)
CRI
CRI
OGN
OGN
Q4 25
$-0.78
Q3 25
$0.32
$0.61
Q2 25
$0.01
$0.56
Q1 25
$0.43
$0.33
Q4 24
$0.42
Q3 24
$1.38
Q2 24
$0.75
Q1 24
$0.78

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CRI
CRI
OGN
OGN
Cash + ST InvestmentsLiquidity on hand
$184.2M
$574.0M
Total DebtLower is stronger
$8.6B
Stockholders' EquityBook value
$864.6M
$752.0M
Total Assets
$2.5B
$12.9B
Debt / EquityLower = less leverage
11.49×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CRI
CRI
OGN
OGN
Q4 25
$574.0M
Q3 25
$184.2M
$672.0M
Q2 25
$338.2M
$599.0M
Q1 25
$320.8M
$547.0M
Q4 24
$675.0M
Q3 24
$763.0M
Q2 24
$704.0M
Q1 24
$575.0M
Total Debt
CRI
CRI
OGN
OGN
Q4 25
$8.6B
Q3 25
$8.8B
Q2 25
$8.9B
Q1 25
$9.0B
Q4 24
$8.9B
Q3 24
$8.7B
Q2 24
$8.7B
Q1 24
$8.7B
Stockholders' Equity
CRI
CRI
OGN
OGN
Q4 25
$752.0M
Q3 25
$864.6M
$906.0M
Q2 25
$853.9M
$733.0M
Q1 25
$847.2M
$542.0M
Q4 24
$472.0M
Q3 24
$493.0M
Q2 24
$144.0M
Q1 24
$48.0M
Total Assets
CRI
CRI
OGN
OGN
Q4 25
$12.9B
Q3 25
$2.5B
$13.6B
Q2 25
$2.5B
$13.5B
Q1 25
$2.3B
$13.2B
Q4 24
$13.1B
Q3 24
$12.8B
Q2 24
$12.2B
Q1 24
$11.9B
Debt / Equity
CRI
CRI
OGN
OGN
Q4 25
11.49×
Q3 25
9.74×
Q2 25
12.14×
Q1 25
16.52×
Q4 24
18.81×
Q3 24
17.75×
Q2 24
60.11×
Q1 24
181.54×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CRI
CRI
OGN
OGN
Operating Cash FlowLast quarter
$-128.0M
$141.0M
Free Cash FlowOCF − Capex
$-144.1M
$96.0M
FCF MarginFCF / Revenue
-19.0%
6.4%
Capex IntensityCapex / Revenue
2.1%
3.0%
Cash ConversionOCF / Net Profit
-11.04×
TTM Free Cash FlowTrailing 4 quarters
$538.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CRI
CRI
OGN
OGN
Q4 25
$141.0M
Q3 25
$-128.0M
$264.0M
Q2 25
$40.3M
$220.0M
Q1 25
$-48.6M
$75.0M
Q4 24
$390.0M
Q3 24
$141.0M
Q2 24
$332.0M
Q1 24
$76.0M
Free Cash Flow
CRI
CRI
OGN
OGN
Q4 25
$96.0M
Q3 25
$-144.1M
$218.0M
Q2 25
$24.1M
$181.0M
Q1 25
$-59.0M
$43.0M
Q4 24
$335.0M
Q3 24
$99.0M
Q2 24
$300.0M
Q1 24
$30.0M
FCF Margin
CRI
CRI
OGN
OGN
Q4 25
6.4%
Q3 25
-19.0%
13.6%
Q2 25
4.1%
11.4%
Q1 25
-9.4%
2.8%
Q4 24
21.0%
Q3 24
6.3%
Q2 24
18.7%
Q1 24
1.8%
Capex Intensity
CRI
CRI
OGN
OGN
Q4 25
3.0%
Q3 25
2.1%
2.9%
Q2 25
2.8%
2.4%
Q1 25
1.6%
2.1%
Q4 24
3.5%
Q3 24
2.7%
Q2 24
2.0%
Q1 24
2.8%
Cash Conversion
CRI
CRI
OGN
OGN
Q4 25
Q3 25
-11.04×
1.65×
Q2 25
90.37×
1.52×
Q1 25
-3.13×
0.86×
Q4 24
3.58×
Q3 24
0.39×
Q2 24
1.70×
Q1 24
0.38×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CRI
CRI

Sales Channel Directly To Consumer$362.3M48%
Sales Channel Through Intermediary$283.8M37%
Other$110.4M15%
Gift Cards$1.3M0%

OGN
OGN

Segment breakdown not available.

Related Comparisons